Soleno Therapeutics Presents Updated Safety and Efficacy Data from Clinical Trial

Soleno Therapeutics (NASDAQ:SLNO) presented new efficacy data from the pilot clinical trial of Diazoxide Choline Controlled-Release Tablet treating Prader-Willi syndrome at the International Meeting of Pediatric Endocrinology.
As quoted in the press release:

The data were presented by Virginia Kimonis, M.D., Division of Genetics and Metabolism, School of Medicine, University of California, Irvine, and Principal Investigator of the trial.
The purpose of the study was to assess the safety and efficacy of multiple dose levels of DCCR in subjects ages 10-22 years with genetically-confirmed PWS. The study consisted of a 10-week open-label treatment phase, during which subjects were escalated from 1.5 mg/kg to a maximum of 5.1 mg/kg of DCCR and then treated stably for the remainder of the phase. Subjects with an improvement in hyperphagia and/or an increase in resting energy expenditure during the open-label phase were classified as responders and were eligible to enter a 4-week double-blind placebo-controlled withdrawal treatment phase, in which they were randomized to DCCR or placebo.

Click here to read the full press release.

Source: globenewswire.com